Algoraceutics - Legal Perspectives on Artificial Intelligence in Drug Discovery and Development (Law for Professionals)

個数:

Algoraceutics - Legal Perspectives on Artificial Intelligence in Drug Discovery and Development (Law for Professionals)

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    【重要ご説明事項】
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 181 p.
  • 商品コード 9783032385369

Full Description

This book explores how artificial intelligence is transforming the pharmaceutical industry and examines the legal challenges arising from its integration into every stage of the drug lifecycle. From target identification, molecular design, and clinical development to regulatory approval, manufacturing, and pharmacovigilance, the volume provides a comprehensive legal framework for understanding what the author terms algoraceutics, the growing convergence of artificial intelligence and pharmaceutical innovation. 
Combining insights from information technology law, pharmaceutical regulation, civil liability, intellectual property, competition law, and data governance, the book explains how contemporary AI systems, including machine learning models, generative AI, digital twins, and autonomous research platforms, are reshaping drug discovery and development. It analyzes the opportunities created by these technologies alongside their legal implications, including questions of inventorship, product liability, algorithmic transparency, explainability, patient protection, and access to data. 
Particular attention is devoted to the European regulatory framework, including the AI Act, the Product Liability Directive, the Data Act, the European Health Data Space, and the evolving guidance of the European Medicines Agency and the U.S. Food and Drug Administration. The book further examines cutting-edge issues such as AI-assisted pharmaceutical inventions, digital twins and in silico clinical trials, algorithmic decision-making in research, and the role of explainability techniques such as SHAP and LIME in regulatory and judicial proceedings. 
Written from an international perspective and grounded in both legal doctrine and regulatory practice, this timely work serves as an authoritative guide for academics, legal practitioners, regulators, and professionals working at the intersection of law, artificial intelligence, biotechnology, and the life sciences. It offers a rigorous yet accessible analysis of one of the most significant technological transformations shaping the future of healthcare and pharmaceutical innovation.

最近チェックした商品